| HOME >> BIOLOGY >> TECHNOLOGY |
TORONTO, Feb. 1, 2013 /PRNewswire/ -- Axela Inc. announced it has appointed AmeriTech Advisors healthcare investment banking team to respond to recent strategic interest from life science industry companies. This involves licensing or sale of rights to certain of the company's recently developed multiplex tests and proprietary platform technologies.
Over the last 2 years Axela has successfully transformed itself from being an engineering based, life-science tools company, into a strategically focused solutions provider, poised to exploit large market opportunities in Cancer, Immunology, Specialty Diagnostic and Life Science markets. Axela has focused its MDX applications on rapidly growing markets which demand the combination of high numbers of gene and/or protein markers, rapid results and competitive pricing.
Axela's Flow-thru Array® platform addresses the gap that exists between multiplexed nucleic acid PCR and high density DNA/RNA arrays. The Ziplex® platform is more cost effective and unlike existing approaches, can be readily integrated into established laboratory workflows while measuring 125-150 genes. Recently, capabilities have been expanded to include fully automated multiplex protein analysis, offering significant advantages over bead or plate based platforms. Ziplex, which is patented with extensive freedom to operate, can simultaneously measure more than 50 proteins rapidly while consuming only a few microliters of sample. Performance has been demonstrated in infectious diseases, traumatic brain injury, and allergy testing applications.
Axela has also significantly advanced the company's second generation diffractive optics platform in collaboration with SONY DADC as part of a development program called ClearDx. The result is a cost efficient and very flexible protein multiplexing platform designed to move the delivery of Personalized Medicine closer to the
'/>"/>
| SOURCE AmeriTech Advisors Copyright©2012 PR Newswire. All rights reserved |